Alzheimer’s Disease (AD) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
ALZHEIMER’S DISEASE
• Alzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affect memory, cognition, and function. Alzheimer’s disease is the most common cause of dementia among older people. Dementia is nothing but the loss of cognitive functioning of thinking, remembering, and reasoning and behavioral abilities, which will interfere with a person’s daily life and activities.
• Dementia ranges from mild to the most severe stage of severity, where the person depends entirely on others for primary activities of life. Age and genetic inheritance are the key risk factors for developing Alzheimer’s disease.
• Currently, there is no therapeutic cure available for Alzheimer’s disease; however, available drugs can lower symptoms or severity of the disease.
• Although many companies have invested in the development of a new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in the condition of the patient, and many of those investigational candidates failed to provide a significant increase in patients condition during phase three clinical trials.
• Symptomatic treatments include the drugs that are aimed at cognitive enhancement or control of neuropsychiatric symptoms and works typically through neurotransmitter mechanisms; disease-modifying therapies or treatments (DMTs) that prevent, delay, or slow progression and target the underlying pathophysiologic amyloid-related mechanisms. Stem cell therapies were also included in the category.
• Some products are available in the market to control ads like Color Cards Activity, Color-Coded Therapy, which are designed to stimulate the mind and sense. Alzheimer’s games and puzzles and eating dishes are available in the market for brain activity.
• The U.S. Food and Drug Administration (FDA) has approved two types of medications like cholinesterase inhibitors (Aricept, Razadyne, Exelon) and memantine (Namenda) for treating the cognitive symptoms of Alzheimer’s disease more than a decade ago.
• The AD treatment pipeline is robust consisting of 112 molecules, among which 26 of 35 trials are in phase III, 63 agents of 75 tests are in phase II, and 23 fragments of 25 trials are in phase I. The mechanisms of actions of the agents review in the pipeline include 63% of disease-modifying therapies, 22% of symptomatic cognitive enhancers, and 12% of symptomatic agents, which addresses neuropsychiatric and behavioral changes.
• Some of the agents currently in phase III of Alzheimer’s disease drug development include Aducanumab by Biogen, AVP-786, AZD3293 (LY3314814) BY AstraZeneca and Eli Lilly, AXS-05, CAD106 & CNP520, and Crenezumab.
• Some of the agents currently in phase II of Alzheimer’s disease drug development include ABBV-8E12 by AbbVie, BAN2401 by Eisai, Candesartan, Deferiprone, Formoterol, IONIS MAPTRx, and Nilotinib. Some of the agents currently in phase I of Alzheimer’s disease drug development include AGN-242071 by Allergan, JNJ-63733657 by Janssen, Oxaloacetate (0AA), Telmisartan, and Vorinostat.
• The global Alzheimer’s market is mainly driven by the growing occurrence of diseases specifically in developed countries of the Western region.
• Furthermore, the prevalence of some neurodegenerative diseases like dementia, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development, and increasing alertness about the treatment of Alzheimer’s disease is resulting into increased demand for Alzheimer’s drugs market.
• However, the high cost of the advance drugs may create restraints in underdeveloped countries. Also, awareness about Alzheimer’s disease in the developing regions remains restricted that resulted in obstructive research infrastructure and unbalanced healthcare systems.
• Alzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affect memory, cognition, and function. Alzheimer’s disease is the most common cause of dementia among older people. Dementia is nothing but the loss of cognitive functioning of thinking, remembering, and reasoning and behavioral abilities, which will interfere with a person’s daily life and activities.
• Dementia ranges from mild to the most severe stage of severity, where the person depends entirely on others for primary activities of life. Age and genetic inheritance are the key risk factors for developing Alzheimer’s disease.
• Currently, there is no therapeutic cure available for Alzheimer’s disease; however, available drugs can lower symptoms or severity of the disease.
• Although many companies have invested in the development of a new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in the condition of the patient, and many of those investigational candidates failed to provide a significant increase in patients condition during phase three clinical trials.
• Symptomatic treatments include the drugs that are aimed at cognitive enhancement or control of neuropsychiatric symptoms and works typically through neurotransmitter mechanisms; disease-modifying therapies or treatments (DMTs) that prevent, delay, or slow progression and target the underlying pathophysiologic amyloid-related mechanisms. Stem cell therapies were also included in the category.
• Some products are available in the market to control ads like Color Cards Activity, Color-Coded Therapy, which are designed to stimulate the mind and sense. Alzheimer’s games and puzzles and eating dishes are available in the market for brain activity.
• The U.S. Food and Drug Administration (FDA) has approved two types of medications like cholinesterase inhibitors (Aricept, Razadyne, Exelon) and memantine (Namenda) for treating the cognitive symptoms of Alzheimer’s disease more than a decade ago.
• The AD treatment pipeline is robust consisting of 112 molecules, among which 26 of 35 trials are in phase III, 63 agents of 75 tests are in phase II, and 23 fragments of 25 trials are in phase I. The mechanisms of actions of the agents review in the pipeline include 63% of disease-modifying therapies, 22% of symptomatic cognitive enhancers, and 12% of symptomatic agents, which addresses neuropsychiatric and behavioral changes.
• Some of the agents currently in phase III of Alzheimer’s disease drug development include Aducanumab by Biogen, AVP-786, AZD3293 (LY3314814) BY AstraZeneca and Eli Lilly, AXS-05, CAD106 & CNP520, and Crenezumab.
• Some of the agents currently in phase II of Alzheimer’s disease drug development include ABBV-8E12 by AbbVie, BAN2401 by Eisai, Candesartan, Deferiprone, Formoterol, IONIS MAPTRx, and Nilotinib. Some of the agents currently in phase I of Alzheimer’s disease drug development include AGN-242071 by Allergan, JNJ-63733657 by Janssen, Oxaloacetate (0AA), Telmisartan, and Vorinostat.
• The global Alzheimer’s market is mainly driven by the growing occurrence of diseases specifically in developed countries of the Western region.
• Furthermore, the prevalence of some neurodegenerative diseases like dementia, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development, and increasing alertness about the treatment of Alzheimer’s disease is resulting into increased demand for Alzheimer’s drugs market.
• However, the high cost of the advance drugs may create restraints in underdeveloped countries. Also, awareness about Alzheimer’s disease in the developing regions remains restricted that resulted in obstructive research infrastructure and unbalanced healthcare systems.
